Product Development Pipeline
TScan’s technology platform has the potential to uncover new targets in a variety of diseases, including cancer, autoimmunity, and infectious disease. TScan is initially focused on cancer, with programs in both liquid and solid tumors.
Liquid Tumor Program
Solid Tumor Program
Leveraging our disruptive new technology platform that enables us to rapidly discover new targets and new TCRs directly from patients, we are building a growing collection of therapeutically active TCRs with diverse anti-tumor targets. Ultimately, this repository will be used to provide customized therapies for diverse groups of patients based on their specific tumor and HLA type.
Because life-changing therapies should be for everyone.